Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

DiCE

Sanofi reception

Medivation unimpressed with Sanofi’s offer

CEO says the offer “substantially undervalues” the oncology specialist

Sanofi reception

Sanofi makes $9.3bn unsolicited bid for Medivation

Hopes to boost oncology business with fast-growing prostate cancer drug Xtandi

National Institute for Health and Care Excellence NICE logo

NICE changes tack on Sanofi’s prostate cancer drug Jevtana

Approves the therapy for NHS use after accepting undisclosed additional discount 

- PMLiVE

Sanofi opens UK bioscience partnering office

Locates new unit at the Stevenage Bioscience Catalyst

Sanofi reception

Sanofi takeover bid rebuffed by Medivation

Had sought to boost its portfolio by acquiring the US cancer therapies firm

- PMLiVE

Pfizer’s PCSK9 inhibitor clears another phase III trial

Bococizumab will compete with Praluent and Repatha if it reaches the market

- PMLiVE

Sanofi appoints Dr Yong-Jun Liu as head of research

He brings experience from MedImmune and the Baylor Research Institute

- PMLiVE

Dr Ameet Nathwani moves from Novartis to Sanofi

He becomes executive vice president, group chief medical officer

Sanofi appoints Diane Souza and Thomas Südhof

They join the board as independent directors

Sanofi reception

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Makes the US biotech's discovery engine a core part of its R&D portfolio

- PMLiVE

First round to Amgen in PCSK9 patent battle with Sanofi

US court concludes Praluent has infringed rival cholesterol drug Repatha

Sanofi reception

Sanofi’s sarilumab beats Humira in head-to-head trial

Rheumatoid arthritis candidate was more effective than AbbVie's market-leader

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links